“Deucravacitinib Long-Term Efficacy Through 4 years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program” (2024) SKIN The Journal of Cutaneous Medicine, 8(4), p. s408. doi:10.25251/skin.8.supp.408.